TY  - JOUR
AU  - Gutierrez, Martin
AU  - Moreno, Victor
AU  - Heinhuis, Kimberley M
AU  - Olszanski, Anthony J
AU  - Spreafico, Anna
AU  - Ong, Michael
AU  - Chu, Quincy
AU  - Carvajal, Richard D
AU  - Trigo, José
AU  - Ochoa de Olza, Maria
AU  - Provencio, Mariano
AU  - De Vos, Filip Yves
AU  - De Braud, Filippo
AU  - Leong, Stephen
AU  - Lathers, Deanne
AU  - Wang, Rui
AU  - Ravindran, Palani
AU  - Feng, Yan
AU  - Aanur, Praveen
AU  - Melero, Ignacio
PY  - 2020
DO  - 10.1158/1078-0432.CCR-20-1830
UR  - http://hdl.handle.net/10668/16546
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
AB  - This phase I/IIa study (NCT02737475) evaluated the safety and activity of BMS-986178, a fully human OX40 agonist IgG1 mAb, ± nivolumab and/or ipilimumab in patients with advanced solid tumors. Patients (with non-small cell lung, renal cell, bladder,...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Cohort Studies
KW  - Female
KW  - Humans
KW  - Ipilimumab
KW  - Male
KW  - Middle Aged
KW  - Neoplasms
KW  - Nivolumab
KW  - Receptors, OX40
KW  - Treatment Outcome
TI  - OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
TY  - research article
VL  - 27
ER  -